Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
50,382,562
-
Share change
-
-1,365,014
-
Total reported value
-
$3,963,254,277
-
Put/Call ratio
-
299%
-
Price per share
-
$78.65
-
Number of holders
-
287
-
Value change
-
-$107,357,997
-
Number of buys
-
142
-
Number of sells
-
120
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q4 2022
As of 31 Dec 2022,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
287 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,382,562 shares.
The largest 10 holders included
Capital Research Global Investors, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Neuberger Berman Group LLC, STATE STREET CORP, FRANKLIN RESOURCES INC, FMR LLC, Fisher Asset Management, LLC, and SCHRODER INVESTMENT MANAGEMENT GROUP.
This page lists
287
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.